Endometriosis is an inflammatory illness that affects millions of women worldwide, causing excruciating pelvic pain, menstrual abnormalities, and infertility. While surgery offers a cure and ...

Recent study on dietary modifications and supplement use for endometriosis pain aimed to investigate the effectiveness of ...

Company executives had seen the drug as a potential multi-billion dollar opportunity in women’s health. New drugs for obesity ...

A landmark 30-year study of over four million women in England has revealed that women with endometriosis-associated ...

The women’s health focused company acquired the drug for up to $954 million in 2021 through the acquisition of Forendo Pharma.

Organon is terminating development of its endometriosis drug after the Phase II trial failed to show any benefit. The ELENA ...

Organon will discontinue its OG-6219 clinical-development program, after the investigational candidate failed to meet its primary efficacy endpoint in treating endometriosis-related pain.

A landmark 30-year study of over four million women in England has revealed that women with endometriosis-associated ...

Organon (NYSE: OGN), a global healthcare company with a focus on women’s health, today announced that the Phase 2 ELENA proof-of-concept study evaluating the investigational candidate OG-6219 in ...

Organon (NYSE:OGN) stock is in focus as the company halts OG-6219 development after a Phase 2 trial in endometriosis-related pain fails. Read more here.